Evidence map›Paper›PMID 29732373›Full record

ReviewFrontiers in molecular biosciences2018

Toward Developing Chemical Modulators of Hsp60 as Potential Therapeutics.

Qianli Meng, Bingbing X Li, Xiangshu Xiao

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in molecular biosciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Chaperonin in health and disease.Molecular biomedicine · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Qianli MengProgram in Chemical Biology, Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, OR, United States.
Bingbing X LiProgram in Chemical Biology, Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, OR, United States.
Xiangshu XiaoProgram in Chemical Biology, Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, OR, United States.
Oregon Health & Science University · US

Funding

Targeting Hsp60 to Inhibit CREB-mediated Gene TranscriptionR01GM122820 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI XIAO, XIANGSHU · 2017 to 2023
$1.9M
Targeting EWS-ATF1 in CCSSTR21CA220061 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI XIAO, XIANGSHU · 2017 to 2018
$368k
NCI NIH HHS R21 CA220061NIGMS NIH HHS R01 GM122820
6 · The paper itself

Abstract

The 60 kDa heat shock protein (Hsp60) is classically known as a mitochondrial chaperonin protein working together with co-chaperonin 10 kDa heat shock protein (Hsp10). This chaperonin complex is essential for folding proteins newly imported into mitochondria. However, Hsp60, and/or Hsp10 have also been shown to reside in other subcellular compartments including extracellular space, cytosol, and nucleus. The proteins in these extra-mitochondrial compartments may possess a wide range of functions dependent or independent of its chaperoning activity. But the mechanistic details remain unknown. Mutations in

Indexed as

autoimmunecancerchaperoneGroELGroESHsp10Hsp60inhibitor

Identifiers

PMID29732373
PMCPMC5920047
OpenAlexW2799662254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.